# Human Leukocyte Antigen (HLA) Mismatched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation

> **NCT06809712** · PHASE1 · RECRUITING · sponsor: **He Huang** · enrollment: 29 (estimated)

## Conditions studied

- Hematologic Disease

## Interventions

- **DRUG:** Busulfan (Busulfex)
- **DRUG:** Cyclophosphamide (CTX)
- **DRUG:** Fludarabine (Fludara)
- **DRUG:** Semustine (MeccNU)

## Key facts

- **NCT ID:** NCT06809712
- **Lead sponsor:** He Huang
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-08-04
- **Primary completion:** 2026-10-31
- **Final completion:** 2027-10-31
- **Target enrollment:** 29 (ESTIMATED)
- **Last updated:** 2025-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06809712

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06809712, "Human Leukocyte Antigen (HLA) Mismatched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06809712. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*